All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Measurement of trough imatinib plasma levels in patients with CML does not significantly correlate with treatment response but may be succesfully used in selected patients for dosage adjustment.

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F10%3A10215602" target="_blank" >RIV/61989592:15110/10:10215602 - isvavai.cz</a>

  • Result on the web

  • DOI - Digital Object Identifier

Alternative languages

  • Result language

    angličtina

  • Original language name

    Measurement of trough imatinib plasma levels in patients with CML does not significantly correlate with treatment response but may be succesfully used in selected patients for dosage adjustment.

  • Original language description

    In order to analyze the impact of IPL measurement on treatment results we have introduced the determination of IPL into our laboratory follow-up of CML patients in 2007. IPL were measured by UHPLC-TMS. 553 samples from 112 patients with CML treated at least 18 months and between 24?6 hours after the ingestion were used for statistics. We did not found correlation between IPL and probability of achievement of optimal cytogenetic or molecular response. We found high IPL inter-individual (394-3133 mg/l) and intra-individual variability (14.2-43.3%). In two patients with low IPL dose escalation led to IPL increase and improvement of treatment response. We were not able to demonstrate a clear correlation between IPL and response to imatinib therapy in our group of patients with CML. On the other hand in selected patients with low IPL and suboptimal response we were able to demonstrate that escalation of imatinib dose lead to optimal treatment response.

  • Czech name

  • Czech description

Classification

  • Type

    D - Article in proceedings

  • CEP classification

    FD - Oncology and haematology

  • OECD FORD branch

Result continuities

  • Project

    Result was created during the realization of more than one project. More information in the Projects tab.

  • Continuities

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Others

  • Publication year

    2010

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Article name in the collection

    Haematologica: the hematology journal

  • ISBN

  • ISSN

    0390-6078

  • e-ISSN

  • Number of pages

    2

  • Pages from-to

  • Publisher name

    Fondazione Ferrata Storti

  • Place of publication

    Pavia

  • Event location

    Barcelona, Spain

  • Event date

    Jun 10, 2010

  • Type of event by nationality

    EUR - Evropská akce

  • UT code for WoS article

    000279051301143